House Report Challenges Pharma Argument That High Prices Fund R&D

By John Wilkerson / September 30, 2020 at 4:56 PM

Celgene hiked the price of Revlimid to meet sales goals that determine executive compensation and to make it difficult for other companies to research competing cancer drugs, according to a report by the House Oversight Committee.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.